Table 1.
Level of malondialdehyde (MDA) and gluathione, ALT, AST in groups.
| Parameters | Control (group1; n = 8) | CCl4 3 days (group 2; n = 8) | CCl4 +genistein (group 3; n = 8) | CCl4 7 days (group 4; n = 8) | CCl4 +genistein (group 5; n = 7) |
|
| |||||
|---|---|---|---|---|---|
| ALT (IU/L) | 103.85 ± 55.58 | 723.62 ± 301.00 | 361.50 ± 39.89 (a) | 454.14 ± 56.66 | 379.14 ± 42.94 (b) |
|
| |||||
| AST (IU/L) | 239.14 ± 82.05 | 867.00 ± 290.26 | 660.37 ± 84.87 (b) | 726.28 ± 137.40 | 561.00 ± 59.21 |
|
| |||||
| Plasma MDA (nmol/ML) | 2.50 ± 0.54 | 4.14 ± 1, 11 | 3.20 ± 0.66 | 5.51 ± 0.71 | 3.4 ± 0.50 (c) |
|
| |||||
| Liver tissue MDA nmol/gr tissue | 19.05 ± 1.43 | 27.02 ± 2.54 | 23.17 ± 2.82 (d) | 33.78 ± 2.04 | 27.20 ± 1.68 (c) |
|
| |||||
| Liver tissue gluthatione μmol/mg tissue | 10.48 ± 0.42 | 8.72 ± 1.30 | 10.45 ± 1.31 (e) | 7.97 ± 1.41 | 9.83 ± 0.88 (e) |
ALT: Alanine aminotrasferase, AST: Aspartate aminotransferase, MDA: Malondialdehyde.
(a) P < .001; significantly lower in group 3 (CCl4 +genistein) than in group 2 (CCl4)
(b) P < .05; significantly lower in group 3 (CCl4 +genistein) than in group 2 (CCl4) and in group 5 (CCl4 +genistein) than in group 4 (CCl4).
(c) P < .001; significantly lower in group 5 (CCl4 +genistein) than in group 4 (CCl4).
(d) P < .001; significantly lower in group 3 (CCl4 +genistein) than in group 2 (CCl4).
(e) P < .05: significantly increased in group 3 (CCl4 +genistein) than in group 2 (CCl4); in group 5 (CCl4 +genistein) in than group 4 (CCl4).